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New indan-1-one derivatives (8 examples) with amino acid fragments were synthesized through the 
N-acylation of the amino acids by 2-(3-oxo-2,3-dihydro-1H-inden-5-yloxy)acetic acid using the 
method of activated N-hydroxysuccinimide esters. To obtain corresponding methyl esters 
(2 examples) two ways were possible: the N-acylation of the amino acid methyl esters by 2-(3-oxo-
2,3-dihydro-1-inden-5-yloxy)acetic acid through the activated imidazole derivatives or methylation 
of the carboxylic function of preformed N-{[(1-oxoindan-6-yl)oxy]acetyl}amino acids. 
________________________________________________________________________________ 
Introduction 
Compounds containing an indane 
fragment are objectively widely represented in 
nature. The variability of such structures is 
provided by different types of substituents, not 
only in the benzene ring, but also those 
presented in positions 1-3: this fragment of the 
molecule can be saturated or can hold a double 
bond, or functional groups mainly hydroxy or 
keto groups. 
Among natural indanes, probably, the 
class of pterosins is most meticulously studied 
(Figure 1). These sesquiterpenes, contained in 
various fern species, have interested researchers 
for their bioactivity [1, 2], but, unfortunately, 
many of the pterosins are highly toxic. So, it is 
not surprising that in recent years there have 
been a lot of experiments to creation bioactive 
substances with an indane fragment devoid of 
this shortcoming, and many tries had been 
successful [3–5].  
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Figure 1. Pterosins – naturally occurring indan-1-ones. 
 
In particular, it has been interesting and 
beneficial for medicinal chemistry to combine 
the indane cycle with the amino acid residue in 
structures of varying complexity. Among these 
molecules (Figure 2) we can find anti-
hypertensive agent 1 [3], compound 2 with anti-
diabetic activity [4], and antipsoriasis agent 3 
[5]. That is why the purpose of the present work 
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was to obtain new amino acid derivatives of 
indane.  
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Figure 2. Bioactive indane derivatives with amino acid 
fragments. 
 
As a base object for modification we 
chose 6-hydroxyindan-1-one 4. Firstly, its 
molecule contains a phenolic OH group, 
convenient for connection of the amino acid 
residue via an amide bond with a hydroxylacetic 
linker; furthermore, exactly the indan-1-one 
system is observed in natural high-bioactive 
pterosins (Figure 1). In addition, indanones are 
a convenient material for conversion into a 
variety of related derivatives: indanes, hydroxy- 
and aminoindanes. 
Studies of 6-hydroxyindan-1-on began in 
the 1920s with the works of Ingold and Piggott 
[6], and while in subsequent years the number 
of publications devoted to derivatives of the 
indane series has increased significantly [7]; and 
in some studies the synthetic possibilities of this 
molecule was been shown. For example, the 
using of 6-hydroxyindan-1-one 4 proved to be 
convenient for the preparation of Ladostigil 
(TV-3326) (Scheme 1), such substance 
demonstrates excellent results in the treatment 
of neurodegenerative disorders (Parkinsonism, 
Alzheimer's disease) [8].  
 
HN
ON
O
O
HO
Ladostigil
4 steps
4  
Scheme 1. 6-Hydroxyindan-1-one in Ladostigil synthesis 
 
Known at first only as a synthetic 
compound, indanone 4 was recently isolated in 
nature: beside the pyridine alkaloids, 
polyphenols and cinnamic acids, this compound 
was isolated from the plant Scrophularia 
ningpoensis, known in traditional Chinese 
medicine due to myocardioprotective 
properties [9]. 
 
Results and discussion 
Modification of indanone 4 with a 
hydroxyacetic fragment was carried out 
according to a scheme analogous to that 
described in the early publication [10] 
(Scheme 2); however for hydrolysis of ester 5 
not acid but basic medium was used. (It had 
been noted that water solution of potash was 
implemented for such reaction; and using of 
aqueous alkali isn’t recommended because the 
indanone system tends to condense in an 
alkaline medium [11]).  
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Scheme 2. The synthesis of 2-(3-oxo-2,3-dihydro-
1H-inden-5-yloxy)acetic acid 
 
To create the amide bond of acid 6 with 
the NH2 group of amino acids, the classical 
method of activated N-hydroxysuccinimide 
esters was used [12, 13] (Scheme 3). This 
method makes it possible to obtain acylating 
agents (succinimide esters 7) and to acylate the 
NH2 group of the amino acid thought 
consecutive addition of reagents as “one-pot” 
synthesis; and the process conditions are mild, 
which is very important in case of acid 6 
modification.  
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Scheme 3. The N-acylation of the amino acids by 
2-(3-oxo-2,3-dihydro-1H-inden-5-yloxy)acetic acid 
thought the method of N-hydroxysuccinimide esters (R 
see Table 1). 
The benefits of N-hydroxysuccinimide 
esters using became more apparent by a 
comparison it with another method we tried. 
Namely, some amino acid derivatives of 
indanone were obtained in reaction of methyl 
esters of amino acids and the activated 
imidazole derivative of acid 6 [13] (Scheme 4).  
The reactions wich were presented on 
Scheme 4 also carried out in a “one-pot” 
variation; and the yields of methyl esters 10a,c 
can be considered suitable, but they are lower to 
the yields of products 8a,c. 
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Scheme 4. The N-acylation of the amino acids methyl 
esters by 2-(3-oxo-2,3-dihydro-1H-inden-5-yloxy)acetic 
acid thought the activated imidazole derivatives (R see 
Table 1). 
 
An alternative tactic to the obtaining of 
compounds 10a,c could be implemented for the 
next way: the preparation of the amino acid 
derivative 8 through the stage of N-hydroxy-
succinimide ester, and following methylation of 
the carboxylic function with methyl iodide. To 
compare the efficiency of this procedure with 
the reactions on Scheme 4, the methionine 
derivative 10c (Scheme 4) was also obtained by 
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methylation of the corresponding derivative 8c 
(Scheme 5).  
 
O
O
H
N
O
MeOOC
S
Me
10c
8c
v: MeI, K2CO3,
    acetone
v
(85%)  
Scheme 5. Synthesis of ester 10c by methylation of 
acid 8c. 
 
Table 1. List, yields and melting points 
of the products 8, 10 
Pro-
duct 
Initial amino acid 
(R) m.p., °C 
Yeild, 
% 
8a Gly (H) 196–197 57 
8b Nle (n-Bu) 133–134 28 
8c Met (CH2CH2SCH3) 71–72 80 
8d Phe (Bn) 142–143 56 
8e Tyr (CH2(4-OHC6H4)) 197–198 26 
8f Trp (CH2(indol-3-yl)) 148–149 57 
8g 
Cyt 
((CH2)3NHC(NH)
NH2) 
185 dec. 61 
8h β-Ala 195–196 48 
10a Gly (H) 64–65 43 
10c 
Met 
(CH2CH2SCH3) 89–90 
52*/ 
85** 
* Scheme 4 
** Scheme 5 
 
In this case, the total yield of the 
substance 10c from the initial acid 6 after two 
stages was 68%, which is higher than the yield 
following the Scheme 4 using (52%). Therefore 
a strategy based on the production of amino acid 
derivatives of indanone type 8 should be 
considered most suitable not only because these 
products can be obtained easily and in high 
yields, but also because compounds 8 can be 
very convenient raw materials for the synthesis 
of the corresponding methyl esters 10. 
 
Experimental part 
Reaction flow and identity of obtained 
compounds was controlled with TLC on Merck 
F254 plates using chloroform : methanol (19:1, 
v/v) system as eluents. 
1H, 13C NMR spectra were recorded at 
Varian 400 spectrometer operating at 400 MHz 
frequency for 1H and 100 MHz for 13C 
experiments. NMR chemical shifts are reported 
in ppm, in the  scale and are referenced using 
TMS as internal standard.  
IR spectra were recorded on a Perkin 
Elmer BX II spectrometer in KBr pellets.  
Melting points were determined using a 
Kofler-type Leica Galen III micro hot stage 
microscope and uncorrected.  
General procedure for N-acylation of 
the amino acid by acid 6 through the method 
of N-hydroxysuccinimide esters. To a solution 
of 0.21 g (1 mmol) of acid 6 and 0.13 g 
(1.1 mmol) of N-hydroxysuccinimide in 10 ml 
of absolute dioxane at room temperature and 
with vigorous stirring 0.23 g (1.1 mmol) of 
dicyclohexylcarbodiimide was added. The 
reaction mixture was stirred at room 
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temperature for 2–3 h until an activated ester 
was formed (TLC monitoring); then a solution 
of 1.1 mmol of the corresponding amino acid 
and 0.14 g (1.67 mmol) of NaHCO3 in 10 ml of 
water was added. The reaction mixture was 
stirred at room temperature for 2–3 h (TLC 
monitoring); and after the process was finished 
the dicyclohexylurea precipitate was filtered off. 
The filtrate was poured into 50 ml of water and 
the solution was acidified (pH 4–5) with dilute 
HCl. The precipitate formed was filtered off, 
recrystallized from mixture i-PrOH – water 1:1. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
glycine 8a. 1H NMR (DMSO-d6): 2.62 (br. s, 
2H, H2-3), 3.00 (br. s, 2H, H2-2), 3.82 (br. s, 2H, 
NHCH2), 4.59 (s, 2H, OCH2CO), 7.10 (br. s, 
1H, H-7), 7.33 (br. d, J=8.0 Hz, 1H, H-5), 7.49 
(d, J=8.0 Hz, 1H, H-4), 8.48 (br. s, 1H, NH). 
13C NMR (DMSO-d6): 25.3, 37.2, 41.1, 67.6, 
107.0, 124.2, 128.5, 138.4, 149.1, 157.8, 168.6, 
171.7, 206.8. IR (KBr, , cm–1): 3529, 3445, 
3288, 1729, 1664, 1552, 1494, 1311, 1222, 
1071, 836. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}nor-
leucine 8b. 1H NMR (DMSO-d6 : CCl4 1:1): 
0.89 (m, 3H, NHCH[(СН2)3CH3]), 1.28 (m, 4Н, 
NHCH[СН2(СН2)2CH3]), 1.67 (m, 1Н, 
[СНα(СН2)2CH3]), 1.77 (m, 1Н, NHCH[СН–
(СН2)2CH3]), 2.64 (br. t, J=4.3 Hz, 2H, H2-3), 
3.07 (br. t, J=4.3 Hz, 2H, H2-2), 4.27 (m, 1H, 
NHCH[n-Bu]), 4.54 (d, J=14.6 Hz, 1Н, 
OCHCO), 4.59 (d, J=14.6 Hz, 1Н, OCHβCO), 
7.11 (d, J=2.2 Hz, 1H, H-7), 7.30 (dd, 
3J=8.0 Hz, 4J=2.2 Hz, H-5), 7.46 (d, J=8.0 Hz, 
H-4), 8.09 (m, 1H, NH), 12.57 (br. s, 1H, 
COOH). 1H NMR (CDCl3): 0.90 (m, 3H, 
NHCH[(СН2)3CH3]), 1.34 (m, 4Н, 
NHCH[СН2(СН2)2CH3]), 1.80 (m, 1Н, 
[СНα(СН2)2CH3]), 1.97 (m, 1Н, NHCH[СН–
(СН2)2CH3]), 2.75 (br. t, J=5.0 Hz, 2H, H2-3), 
3.11 (br. t, J=5.0 Hz, 2H, H2-2), 4.58 (s, 2H, 
OCH2CO), 4.72 (m, 1H, NHCH[n-Bu]), 7.00 
(br. d, J=7.2 Hz, 1H, NH), 7.28 (m, 2H, H-5,7), 
7.45 (d, J=8.4 Hz, 1H, H-4). 13C NMR (CDCl3): 
13.8, 22.3, 25.2, 27.3, 37.0, 51.7, 56.6, 67.5, 
107.3, 123.6, 127.9, 138.4, 149.2, 156.8, 168.0, 
171.3, 206.7. IR (KBr, , cm–1): 3380, 2958, 
1700, 1540, 1274, 1220, 1187, 1062, 836. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
methionine 8c. 1H NMR (DMSO-d6 : CCl4 1:1): 
1.91–2.08 (m, 5H, NHCH[CH2СН2SСН3]), 2.43 
(m, 2H, NHCH[CH2СН2SСН3]), 2.64 (m, 2H, 
H2-3), 3.07 (m, 2H, H2-2), 4.42 (m, 1H, 
NHCH[(CH2)2SСН3]), 4.55 (m, 2H, OCH2CO), 
7.12 (br. s, 1H, H-7), 7.29 (br. d, J=8.2 Hz, 
H-5), 7.44 (d, J=8.2 Hz, H-4), 8.17 (br. d, 
J=7.0 Hz, 1H, NH). 13C NMR (DMSO-d6): 
15.2, 25.4, 30.4, 31.0, 37.3, 51.3, 67.5, 106.8, 
124.3, 128.4, 138.4, 149.0, 158.0, 168.4, 173.7, 
206.5. IR (KBr, , cm–1): 3501, 3400, 2935, 
1670, 1519, 1446, 1309, 1256, 1208, 1063, 839. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
phenylalanine 8d. 1H NMR (CDCl3): 2.75 (br. t, 
J=5.2 Hz, 2H, H2-3), 3.11 (br. t, J=5.2 Hz, 2H, 
H2-2), 3.20 (dd, 2J=14.2 Hz, 3J=6.4 Hz, 1Н, 
NHCH[CHPh]), 3.26 (dd, 2J=14.2 Hz, 
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3J=6.4 Hz, 1Н, NHCH[CHβPh]), 4.50 (d, 
J=15.0 Hz, 1Н, OCHCO), 4.55 (d, J=15.0 Hz, 
1Н, OCHβCO), 4.98 (q, J=6.4 Hz, 1H, 
NHCH[Bn]), 6.95 (br. d, J=8.2 Hz, 1H, NH), 
7.13–7.19 (m, 5H, Ph), 7.28 (m, 2H, H-5,7), 
7.42 (d, J=8.0 Hz, 1H, H-4). 1H NMR 
(DMSO-d6): 2.60–2.68 (m, 2H, H2-3), 2.92–
3.05 (m, 3H, H2-2, NHCH[CHPh]), 3.26 (dd, 
2J=13.2 Hz, 3J=3.6 Hz, 1Н, NHCH[CHβPh]), 
4.45–4.61 (m, 3H, OCH2CO, NHCH[Bn], 7.05 
(br. s, 1H, H-7), 7.11–7.29 (m, 6H, H-5, Ph), 
7.47 (d, J=8.2 Hz, 1H, H-4), 8.31 (br. s, 1H, 
NH), 12.87 (br. s, 1H, COOH). 13C NMR 
(DMSO-d6): 25.4, 37.0, 37.2, 53.9, 67.4, 106.9,  
124.1, 127.1, 128.5, 128.9, 129.7, 138.12, 
138.42, 149.0, 157.9, 168.2, 173.3, 206.6. IR 
(KBr, , cm–1): 3412, 3266, 2930, 1673 br, 
1544, 1490, 1306, 1278, 1222, 1186, 1069, 845, 
693. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
tyrosine 8e. 1H NMR (DMSO-d6): 2.64 (br. t, 
J=5.2 Hz, 2H, H2-3), 2.86 (m, 1Н, 
NHCH[CH(4-НОС6Н4)]), 2.95 (m, 1Н, 
NHCH[CH(4-НОС6Н4)]), 3.01 (br. t, J=5.2 Hz, 
2H, H2-2), 4.41 (m, 1Н, NHCH[CH2–
(4-НОС6Н4)]), 4.54 (m, 2Н, OCH2CO), 6.60 (d, 
J=8.3 Hz, 2Н, Н-3,5 (4-НОС6Н4)), 6.96 (d, 
J=8.3 Hz, 2Н, Н-2,6 (4-НОС6Н4)), 7.05 (br. s, 
1H, H-7), 7.24 (br. d, J=8.2 Hz, H-5), 7.47 (d, 
J=8.2 Hz, H-4), 8.22 (d, J=8.0 Hz, 1H, NH), 
9.23 (br. s, 1H, 4-НОС6Н4). 13C NMR 
(DMSO-d6): 25.4, 36.3, 37.3, 54.2, 67.5, 106.9, 
115.62, 124.0, 128.1, 128.5, 130.72, 138,4, 
149.0, 156.5, 157.9, 168.1, 173.4, 201.7. IR 
(KBr, , cm–1): 3384, 2918, 1720, 1703, 1630, 
1544, 1491, 1438, 1278, 1205, 1063, 914, 836, 
794. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
tryptophan 8f. 1H NMR (DMSO-d6): 2.64 (br. t, 
J=4.5 Hz, 2H, H2-3), 3.02 (br. t, J=4.5 Hz, 2H, 
H2-2), 3.12–3.31 (m, 2H, NHCH[CH2(indol-3-
yl)]), 4.49–4.65 (m, 3H, OCH2CO,  
NHCH[CH2(indol-3-yl)]), 6.97 (br. t, J=7.8 Hz, 
1Н, Н-5 (indol-3-yl)), 7.00–7.11 (m, 2Н, 
Н-2,6), 7.14 (br. s, 1H, H-7), 7.22 (br. d, 
J=7.8 Hz, H-5), 7.36 (d, J=7.8 Hz, 1Н, Н-4 
(indol-3-yl)), 7.46 (d, J=7.8 Hz, H-4), 7.56 (d, 
J=7.8 Hz, 1Н, Н-7 (indol-3-yl)), 7.96 (m, 1H, 
NH), 10.79 (s, 1H, NН (indol-3-yl)). 13C NMR 
(DMSO-d6): 25.4, 27.5, 37.3, 53.5, 67.5, 107.1, 
110.3, 112.1, 118.8, 119.1, 121.6, 124.0, 124.4, 
127.9, 128.5, 136.7, 138.4, 149.0, 157.8, 168.0, 
173.8, 206.7. IR (KBr, , cm–1): 3406, 3339, 
1700 br, 1535, 1278, 1222, 1186, 1065, 833, 
745. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
citrulline 8g. 1H NMR (DMSO-d6 : CCl4 1:1): 
1.37–1.46 (m, 2H, NHCH[СН2СН2СН2–
NHCONH2]), 1.61–1.71 (m, 1H, 
NHCH[СН(СН2)2NHCONH2]), 1.75–1.85 (m, 
1H, NHCH[СН(СН2)2NHCONH2]), 2.64 (br. t, 
J=4.5 Hz, 2H, H2-3), 2.95–3.01 (m, 2H, 
NHCH[(СН2)2СН2NHCONH2]), 3.06 (br. t, 
J=4.5 Hz, 2H, H2-2), 4.25–4.32 (m, 1H, 
NHCH[(СН2)3NHCONH2]), 4.56 (s, 2H, 
OCH2CO), 5.93 (br. s, 1H, NHCONH2), 7.10 (d, 
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J=2.2 Hz, 1H, H-7), 7.29 (dd, 3J=8.3 Hz, 
4J=2.2 Hz, H-5), 7.44 (d, J=8.3 Hz, H-4), 8.21 
(d, J=7.6 Hz, 1H, NH). 13C NMR (CDCl3): 25.2, 
27.2, 28.8, 37.1, 52.0, 67.3, 106.7, 124.0, 128.3, 
138.3, 148.8, 157.9, 159.2, 168.0, 173.7, 206.5. 
IR (KBr, , cm–1): 3373, 3317, 2936, 2880, 
1700, 1595, 1440, 1261, 1057, 845. 
N-{[(1-oxoindan-6-yl)oxy]acetyl}-
β-alanine 8h. 1H NMR (DMSO-d6 : CCl4 1:1): 
2.41 (br. t, J=6.6 Hz, 2H, NHCH2CH2), 2.63 
(br. t, J=4.3 Hz, 2H, H2-3), 3.05 (br. t, J=4.3 Hz, 
2H, H2-2), 3.31–3.40 (m, 2H, NHCH2CH2), 
4.46 (s, 2H, OCH2CO), 7.08 (br. s, 1H, H-7), 
7.27 (br. d, J=8.3 Hz, H-5), 7.44 (d, J=8.3 Hz, 
H-4), 8.05 (br. t, J=6.0 Hz, 1H, NH). 13C NMR 
(CDCl3): 25.2, 34.2, 35.0, 37.1, 67.6, 106.8, 
124.0, 128.4, 138.3, 148.8, 157.8, 167.9, 173.3, 
206.5. IR (KBr, , cm–1): 3333, 2924, 1712, 
1650, 1564, 1488, 1427, 1284, 1191, 1063, 845. 
General procedure for N-acylation of 
the amino acid methyl esters by acid 6 
through the activated imidazole derivatives. 
A solution of 0.21 g (1 mmol) of acid 6 and 
0.2 g (1.25 mmol) 1,1'-carbonyldiimidazole in 
10 ml of absolute dioxane vigorous stirring at 
room temperature for 2–2.5 h. To the resulting 
activated imidazole derivative 1.1 mmol of the 
corresponding ester of amino acid 
(hydrochloride) and 0.17 ml (1.25 mmol) of 
Et3N were added. The reaction mixture was 
stirred at 50°C for 2–3 h, then cooled and 
poured into 50 ml of water and. The slowly-
formed precipitate was filtered off, 
recrystallized from mixture i-PrOH – water 1:1. 
Methyl ester of N-{[(1-oxoindan-6-yl)-
oxy]acetyl}glycine 10a. 1H NMR (CDCl3): 2.75 
(br. t, J=5.6 Hz, 2H, H2-3), 3.11 (br. t, J=5.6 Hz, 
2H, H2-2), 3.80 (s, 3H, COOMe), 4.17 (d, 
J=5.8 Hz, 2H, NHCH2COOH), 4.59 (s, 2H, 
OCH2CO), 7.08 (m, 1H, NH), 7.24 (d, 
J=2.7 Hz, 1H, H-7), 7.27 (dd, 3J=8.3 Hz, 
4J=2.7 Hz, H-5), 7.45 (d, J=8.3 Hz, 1H, H-4). 
13C NMR (CDCl3): 25.2, 37.0, 40.8, 52.5, 67.5, 
107.0, 123.6, 127.9, 138.5, 149.2, 156.9, 168.0, 
169.9, 206.5. IR (KBr, , cm–1): 3546, 3451, 
3322, 3036, 2913, 1731, 1706, 1662, 1552, 
1490, 1446, 1245, 1071, 984, 834. 
Methyl ester of N-{[(1-oxoindan-6-yl)-
oxy]acetyl}methionine 10c. 1H NMR (CDCl3): 
2.01–2.13 (m, 4H, NHCH[CH2СНSСН3]), 
2.19–2.27 (m, 1H, NHCH[CH2СНSСН3]), 2.52 
(t, J=7.3 Hz, 2H, NHCH[CH2СН2SСН3]), 2.75 
(br. t, J=5.6 Hz, 2H, H2-3), 3.11 (br. t, J=5.6 Hz, 
2H, H2-2), 3.79 (s, 3H, COOMe), 4.53–4.61 (m, 
2H, OCH2CO), 4.80–4.86 (m, 1H, 
NHCH[(CH2)2SСН3]), 7.24 (d, J=2.0 Hz, 1H, 
H-7), 7.25–7.30 (2H+CHCl3, m, H-5, NH), 7.45 
(d, J=8.5 Hz, 1H, H-4). 1H NMR (DMSO-d6): 
1.85–2.06 (m, 5H, NHCH[CH2СН2SСН3]), 
2.34–2.50 (m, 2H, NHCH[CH2СН2SСН3]), 2.64 
(br. t, J=5.6 Hz, 2H, H2-3), 3.01 (br. t, J=5.6 Hz, 
2H, H2-2), 3.62 (s, 3H, COOMe), 4.41–4.50 (m, 
1H, NHCH[(CH2)2SСН3]), 4.56–4.69 (m, 2H, 
OCH2CO), 7.07 (br. s, 1H, H-7), 7.31 (br. d, 
J=8.2 Hz, H-5), 7.51 (d, J=8.2 Hz, H-4), 8.59 
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(d, J=7.7 Hz, 1H, NH). 13C NMR (DMSO-d6): 
25.4, 30.5, 37.3, 51.2, 67.4, 106.7, 124.4, 128.5, 
138.4, 149.0, 158.0, 168.6, 172.6, 206.7. IR 
(KBr, , cm–1): 3417, 3064, 2952, 2913, 1731, 
1712, 1688, 1614, 1524, 1488, 1443, 1362, 
1250, 1166, 1057, 990, 903, 831. 
General procedure for methylation of 
COOH group of acids 8. To a solution of 
0.75 mmol of acid 8 in 10 ml of acetone 0.22 g 
(1.6 mmol) of dried and powdered K2CO3 and 
0.1 ml (1.6 mmol) of MeI were added. The 
reaction mixture was refluxed with vigorous 
stirring 1.5–2 h. After the process was finished 
(TLC monitoring) the solution of product was 
separated from inorganic precipitate, and 
evaporated in vacuum. The residue was 
recrystallized from mixture i-PrOH – water 1:1. 
 
Conclusions 
So it was shown that the N-acylation of 
amino acids by 2-(3-oxo-2,3-dihydro-1H-inden-
5-yloxy)acetic acid can be easily made using the 
method of N-hydroxysuccinimide esters; and it 
performed the creation of new indan-1-one 
derivatives with various amino acid fragments 
possible. For synthesis of appropriate methyl 
esters not reaction between 2-(3-oxo-2,3-
dihydro-1H-inden-5-yloxy)acetic acid activated 
imidazole derivative and amino acids methyl 
esters but the methylation of the carboxylic 
function of preformed N-{[(1-oxoindan-6-yl)-
oxy]acetyl}amino acids can be used. 
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